SynthesisMolecular neurobiology2026
Neural Stem Cells and Inflammation Modulation in Preclinical Spinal Cord Injury: A Systematic Review.
Synthesis in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An integrated hydrogel-V3 interneuron therapy promotes functional repair of spinal cord injury via neural circuit reconstruction and microenvironment remodeling.Bioactive materials · 2026Article
- Reprogramming the Inflammatory Response to Promote Neural Stem Cell Function After Spinal Cord Injury.Molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is a debilitating condition characterized by primary mechanical trauma followed by secondary neuroinflammation. Neural stem cells (NSCs) hold promise for SCI repair through their regenerative and immunomodulatory properties, including the promotion of anti-inflammatory macrophage phenotypes. However, the specific mechanisms by which NSCs modulate inflammation in preclinical models remain heterogeneous. This systematic review synthesizes evidence from rodent studies to elucidate these mechanisms and inform translational strategies. A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science up to August 2025, using terms related to SCI, inflammation, and NSC transplantation. Preclinical studies involving NSC interventions in rodent SCI models were included if they assessed inflammatory outcomes. Data extraction focused on study characteristics, NSC administration, inflammation markers (e.g., cytokines, macrophage polarization), and functional recovery. Quality assessment followed SYRCLE guidelines, with narrative synthesis due to methodological heterogeneity. Ten studies met inclusion criteria, predominantly using rat or mouse contusion/compression models. NSC transplantation, often with adjuncts like hydrogels or genetic modifications (e.g., Wnt4, E-cadherin), consistently reduced proinflammatory markers (IL-1β, IL-6, and TNF-α) in 70% of studies (p < 0.05), with three demonstrating shifts toward anti-inflammatory M2 macrophages (e.g., increased CD206, arginase-1). Subacute timing enhanced efficacy, correlating with improved locomotor scores (e.g., BBB) and reduced glial scarring. However, 30% reported nonsignificant effects, attributed to chronic models or delivery methods. NSC transplantation modulates SCI inflammation by suppressing proinflammatory pathways and fostering M2 polarization, which facilitates repair. These findings point out the advantages of optimized NSC strategies for clinical translation.
Indexed as
Identifiers
41703313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.